Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Its Reblozyl (luspatercept) therapy for rare anemias, which is licensed to Bristol-Myers Squibb , was approved to treat anemia in adults with beta thalassemia, who require regular red blood cell ...

Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Reblozyl is supplied as 25mg and 75mg lyophilized powder in single-dose vials for reconstitution and subcutaneous administration. The product is expected to be available in 1 week.

Reblozyl (luspatercept) was first approved by the FDA for treatment of anemia related to beta thalassemia in late Q4 2019. The royalties are paid to Acceleron by Bristol-Myers Squibb ( BMY ).

Reblozyl is also approved for the treatment of anemia in adults with beta thalassemia who require RBC transfusions; and for the treatment of anemia failing an ESA and requiring 2 or more RBC units ...

SUMMIT, N.J.& CAMBRIDGE, Mass.---- Celgene Corporation and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration has approved REBLOZYL ® for the treatment of anemia in adult ...

Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes ...

REBLOZYL ® is the first and only erythroid maturation agent approved for use in Canada MONTREAL, Sept. 29, 2020 /CNW/ - Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today ...